Lactic Acidosis is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please or purchase a subscription.

Johns Hopkins Guides provide diagnosis, management, and treatment guidance for infectious diseases, diabetes, and psychiatric conditions. Explore these free sample topics:

Johns Hopkins Guides

~~ The first section of this topic is shown below ~~

CLINICAL

  • Incidence: Mild, asymptomatic hyperlactatemia: 8-15%; Symptomatic hyperlactatemia: 0.5-12%
  • Symptoms: Fatigue, weakness, myalgias, and GI distress, including abdominal pain, abdominal distention, nausea/vomiting, diarrhea. Later can advance to dyspnea, orthostasis, organ failure (hepatic, renal), cardiovascular collapse and death.
  • Mortality: 7% with lactate 5-10 mM, 20-30% with lactate 10-15 mM, 50-60% with lactate >15 mM
  • Caused by NRTI use: d4TddI, AZT. May not occur with 3TC, FTC, ABC, TDF, though listed in package insert as a class effect.
  • Associated with mitochondrial DNA gamma polymerase inhibition, and decrease in mitochondrial DNA
  • May be accompanied by hepatic steatosis (fatty liver), pancreatitis. Fatal liver failure can occur (earliest reports in AZT-treated patients)
  • Increased risk with lower CD4, older age, female sex. Do not use ddI + d4T in pregnancy (FDA warning)

~~ To view the remaining sections of this topic, please
or purchase a subscription ~~

Last updated: November 7, 2011